139 related articles for article (PubMed ID: 9792137)
1. Comment on the appropriateness of The Prostate publishing a trial comparing Permixon to finasteride without a placebo control group.
Gillenwater JY
Prostate; 1998 Nov; 37(3):194. PubMed ID: 9792137
[No Abstract] [Full Text] [Related]
2. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
Zlotta AR; Teillac P; Raynaud JP; Schulman CC
Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
[TBL] [Abstract][Full Text] [Related]
3. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
Carraro JC; Raynaud JP; Koch G; Chisholm GD; Di Silverio F; Teillac P; Da Silva FC; Cauquil J; Chopin DK; Hamdy FC; Hanus M; Hauri D; Kalinteris A; Marencak J; Perier A; Perrin P
Prostate; 1996 Oct; 29(4):231-40; discussion 241-2. PubMed ID: 8876706
[TBL] [Abstract][Full Text] [Related]
4. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.
Marks LS; Hess DL; Dorey FJ; Luz Macairan M; Cruz Santos PB; Tyler VE
Urology; 2001 May; 57(5):999-1005. PubMed ID: 11337315
[TBL] [Abstract][Full Text] [Related]
5. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
Plosker GL; Brogden RN
Drugs Aging; 1996 Nov; 9(5):379-95. PubMed ID: 8922564
[TBL] [Abstract][Full Text] [Related]
6. The value of permixon in benign prostatic hypertrophy.
Reece Smith H; Memon A; Smart CJ; Dewbury K
Br J Urol; 1986 Feb; 58(1):36-40. PubMed ID: 2418902
[TBL] [Abstract][Full Text] [Related]
7. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.
Boyle P; Robertson C; Lowe F; Roehrborn C
BJU Int; 2004 Apr; 93(6):751-6. PubMed ID: 15049985
[TBL] [Abstract][Full Text] [Related]
8. Saw palmetto and finasteride in the treatment of category-III prostatitis/chronic pelvic pain syndrome.
Yang J; Te AE
Curr Urol Rep; 2005 Jul; 6(4):290-5. PubMed ID: 15978232
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP
Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
[TBL] [Abstract][Full Text] [Related]
11. [Is there a rational therapy for symptomatic treatment of benign prostatic hyperplasia with phytogenic drugs? Illustrated with the example of the prostate agent from Serenoa repens (Sabal fructus)].
Schilcher H
Wien Med Wochenschr; 1999; 149(8-10):236-40. PubMed ID: 10483690
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia.
Boyle P; Robertson C; Lowe F; Roehrborn C
Urology; 2000 Apr; 55(4):533-9. PubMed ID: 10736497
[TBL] [Abstract][Full Text] [Related]
13. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.
Sökeland J
BJU Int; 2000 Sep; 86(4):439-42. PubMed ID: 10971268
[TBL] [Abstract][Full Text] [Related]
14. [Permixon in the treatment of benign prostatic hyperplasia].
Gorilovskiĭ LM
Ter Arkh; 1995; 67(8):62-4. PubMed ID: 7482341
[No Abstract] [Full Text] [Related]
15. [Hormonal therapy for benign prostatic hyperplasia].
Sakai H; Kanetake H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
[No Abstract] [Full Text] [Related]
16. [Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon].
Sivkov AV; Kudriavtsev IuV; Medvedev AA; Razumov SV; Kochetov SA
Urologiia; 2004; (5):10-6. PubMed ID: 15560155
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride.
Van Coppenolle F; Le Bourhis X; Carpentier F; Delaby G; Cousse H; Raynaud JP; Dupouy JP; Prevarskaya N
Prostate; 2000 Apr; 43(1):49-58. PubMed ID: 10725865
[TBL] [Abstract][Full Text] [Related]
18. Serenoa repens for benign prostatic hyperplasia.
Wilt T; Ishani A; Mac Donald R
Cochrane Database Syst Rev; 2002; (3):CD001423. PubMed ID: 12137626
[TBL] [Abstract][Full Text] [Related]
19. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review.
Wilt TJ; Ishani A; Stark G; MacDonald R; Lau J; Mulrow C
JAMA; 1998 Nov; 280(18):1604-9. PubMed ID: 9820264
[TBL] [Abstract][Full Text] [Related]
20. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.
Buck AC
J Urol; 2004 Nov; 172(5 Pt 1):1792-9. PubMed ID: 15540722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
